Biosimilars

Utilization Management of Medicare Part D Oncology Drugs

Utilization management for Medicare Part D oral oncology drugs increased between 2010 and 2020, according to a study of formulary files. “Prior authorization was the

Michael Posey July 19, 2023

Biosimilar Cost Savings With “Skinny Labeling”

The Medicare system saved $1.5 billion in costs for just 5 biosimilars with “skinny labels,” a study shows. Skinny-label biosimilars are those with FDA approval

Michael Posey November 29, 2022